Rochester Institute of Technology

Leading spinal researcher develops new tissue regeneration approaches for back pain

Karin Wuertz-Kozak described her lab test equipment as a gym for cells. Stretching and compressions tests using bioreactors—her lab equipment—can make a difference in understanding how cells respond ...
Post-Bulletin

Mayo Clinic Q&A: Could my back pain be degenerative disk disease?

DEAR MAYO CLINIC: I've been struggling with back stiffness and pain for a long time, but it has gotten worse in the last few years. My doctor told me that I have degenerative disk disease. What ...

FDA grants PMA to Synergy’s cervical disc

Synergy Spine Solutions has received premarket approval (PMA) from the US Food and Drug Administration (FDA) for the Synergy ...
Becker's Spine Review

Synergy Spine’s cervical disc earns FDA approval

Synergy Spine Solutions earned the FDA’s premarket approval for its Synergy Disc, according to a Feb. 27 news release. The device is approved for 1-level cervical disc replacement at C3 to C7 for ...
Yahoo Finance

BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease

MELVILLE, N.Y., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator ...
MassDevice

Synergy Spine gets FDA nod for cervical disc

Synergy Spine Solutions announced today that it received FDA premarket approval (PMA) for its Synergy Disc for 1-level ...
Morningstar

Companion Spine Announces FDA Premarket Approval (“PMA”) of the DIAM™ Spinal Stabilization System for the Treatment of Degenerative Disc Disease (“DDD”)

Companion Spine Announces FDA Premarket Approval (“PMA”) of the DIAM™ Spinal Stabilization System for the Treatment of Degenerative Disc Disease (“DDD”) DIAM™ Spinal Stabilization System is the first ...
Nasdaq

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

MELVILLE, N.Y., Feb. 20, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical ...
Business Insider

FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease

HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...